TI: The Use of Ozone-Treated Blood in the Therapy of HIV Infection and Immune Disease: A Pilot Study of Safety and Efficiacy DT: 1991 AU: Gary E. Garber, D. William Cameron, Nanci Hawley-Foss, Donald Greenway, and Michael E. Shannon SO: AIDS 1991, 5:981-984 AB: The use of ozone therapy is reported to be effective in a variety of viral illnesses, including HIV disease. We performed a phase 1 study of ozone blood treatments in 10 patients in whom no significant toxicity was observed. Three patients with moderate immunodeficiency showed improvement in surrogate markers of HIV-associated immune disease. A phase 2 controlled and randomized double- blinded study was initiated comparing reinjection of ozone- treated blood, and reinjection of unprocessed blood for 8 weeks, followed by a 4-week observation period. Ozone had no significant effect on hematologic, biochemical or clinical toxicity when compared with placebo. CD4 cell count, interleukin-2, -interferon, 2-microglobulin, neopterin and p24 antigen were also unaffected by both treatment arms. In conclusion, ozone therapy does not enhance parameters of immune activation nor does it diminish measureable p24 antigen in HIV-infected individuals. Note: It would wise to speak to Dr. Michael Shannon, Director Medical Operations, Canadian National Defence before you put too much weight on this study. In Ed McCabe's "Chronological Ozone Medical References" and "O3 vs AIDS", Mr. McCabe wrote, "Poorly designed because the study only gave 10 cc's of ozone into a muscle (dismissed by Aubourg in 1938 as too painful and ineffective), not I.V., and not enough to do any good, and not for long enough time period." "Poorly executed because during the second half of the too short study, the principals admitted the ozone machine had broken, and wasn't producing any ozone, yet they ignored this fact when they wrote up the second phase of the study!"